Brain natriuretic peptide facilitates severity classification of stable chronic heart failure with left ventricular dysfunction

Sakurai, Shigeki

doi:10.1136/heart.89.6.661

Cited by 18 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In heart failure (HF), plasma natriuretic peptide levels have been established, not only as excellent diagnostic markers (1), but also for the assessment of the severity of disease (2) and prognosis (3). Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are synthesized in the myocardium as their precursors proANP and proBNP, which are then cleaved into the corresponding biologically inactive amino-terminal segments of the precursor molecules (amino-terminal pro-atrial natriuretic peptide [NTproANP] and amino-terminal pro-B-type natriuretic peptide [NT-proBNP], respectively) and the biologically active peptides (ANP and BNP).…”

mentioning

confidence: 99%

Comparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure

Moertl

Berger

Struck³

et al. 2009

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Comparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure

Moertl

Berger

Struck³

et al. 2009

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

“…For chronic heart failure, a widespread disease of increasing incidence [1] and poor prognosis [2], natriuretic peptides have been established as diagnostic markers [3] and as markers for the severity of heart failure [4]. Furthermore, several studies have shown that natriuretic peptides determined at a single time point are excellent prognostic markers for the prediction of adverse outcome in chronic heart failure [5].…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of sequential measurements of amino‐terminal prohormone of B‐type natriuretic peptide in ambulatory heart failure patients

Moertl

Hammer

Huelsmann

et al. 2008

European J of Heart Fail

View full text Add to dashboard Cite

Background: We evaluated the prognostic value of sequential NT-proBNP values in ambulatory heart failure patients after discharge, investigating whether the current value or the recent percent change is more important. Methods and results: In 166 patients, NT-proBNP was measured at discharge from heart failure hospitalisation and three months later. The combined endpoint of death or heart failure rehospitalisation was evaluated after a maximum of 18 months or at follow-up closure. During a mean observation time of 14 ± 4 months, 63 patients (38%) reached the endpoint. In multiple Cox analysis, NT-proBNP three months after discharge (NT-proBNP-3Mo) and NT-proBNP percent change (NT-proBNP-%change) were the only independent predictors of the endpoint among various clinical and laboratory variables. After definition of a high-(n = 83, 57% endpoints) and a low-NT-proBNP patient subgroup (n = 83, 19% endpoints) according to the median NT-proBNP-3Mo (1751 pg/ml), NT-proBNP-%change was the strongest predictor in the high-NT-proBNP subgroup. In the low-NT-proBNP subgroup, NT-proBNP-3Mo was the only independent predictor. Conclusions: In ambulatory heart failure patients, the prognostic value of sequential NT-proBNP measurements depends on the magnitude of the current NT-proBNP value. Recent percent changes in NT-proBNP provide important prognostic information in patients with high NTproBNP but not in patients with low NT-proBNP.

show abstract

“…The cardiac hypertrophy that accompanies myocardial failure causes increased ventricular production of ANP and BNP. 1 These peptides have been established not only as excellent diagnostics markers but also as very useful parameters with which to assess the disease severity 15 and prognosis. 16 The most commonly measured natriuretic peptide, which is used in the diagnosis of HF, is BNP and its precursor N-terminal proBNP (NT-proBNP).…”

Section: Resultsmentioning

confidence: 99%

Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease

Idzikowska

Zielińska

2018

J Int Med Res

View full text Add to dashboard Cite

Midregional pro-atrial natriuretic peptide (MR-proANP), first isolated in 1981, is a novel peptide with multiple biological functions, especially within the cardiovascular system. This peptide plays an important role in many processes, including natriuresis, diuresis, and other physiological and pathophysiological pathways in the human body. Several electronic databases (PubMed, EBSCO, Scopus, and ScienceDirect) were analyzed in the present literature review. The aim of this study was to elucidate the wide roles of MR-proANP, which can be analyzed because of the development of a new sandwich immunoassay, and to determine the possible diagnostic and prognostic implications of MR-proANP on cardiovascular disease and other disorders. The studies discussed in this literature review provide valuable data on the role of ANP in the pathogenesis, diagnostic process, prognosis, and potential therapeutic strategies for disease. Although ANP is mainly associated with cardiovascular disease, it may be used as a biomarker in diabetology, neurology, and metabolic disorders.

show abstract

Brain natriuretic peptide facilitates severity classification of stable chronic heart failure with left ventricular dysfunction

Cited by 18 publications

References 6 publications

Comparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure

Comparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure

Prognostic value of sequential measurements of amino‐terminal prohormone of B‐type natriuretic peptide in ambulatory heart failure patients

Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease

Contact Info

Product

Resources

About